STOCK PURCHASE AGREEMENT between C4 Therapeutics, Inc., Betta Investment (Hong Kong) Limited and Betta Pharmaceuticals Co., Ltd. Dated as of May 29, 2023Stock Purchase Agreement • May 30th, 2023 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Stock Purchase Agreement (this “Agreement”) is made as of May 29, 2023, by and among C4 Therapeutics, Inc., a Delaware corporation (the “Company”), Betta Investment (Hong Kong) Limited, a limited liability company established under the laws of Hong Kong (the “Investor”), and Betta Pharmaceuticals Co., Ltd., a limited liability company established under the laws of PRC and the sole stockholder of the Investor (the “Parent”).
LICENSE AND COLLABORATION AGREEMENT By and Between C4 THERAPEUTICS, INC., and BETTA PHARMACEUTICALS CO., LTD. May 29, 2023License and Collaboration Agreement • May 30th, 2023 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances)
This License and Collaboration Agreement (the “Agreement”) is entered into as of May 29, 2023 (the “Effective Date”), by and between C4 Therapeutics, Inc., a corporation having a place of business at 490 Arsenal Way, Suite 120, Watertown, MA 02472, the United States (“C4T”), and Betta Pharmaceuticals Co., Ltd., a company having a place of business at 355 Xingzhong Road, Linping District, Hangzhou, Zhejiang, P.R. China 311100 (“Licensee”).
